



PTO-5449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>August 28, 2003</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-001 (formerly NIIN-PO1-011)	APPLICATION NO. 10/003,740	
	APPLICANT Mel Epstein, <i>et al.</i>		
	FILING DATE October 31, 2001	CONFIRMATION NO. 2709	GROUP 1614

5	AA2	5,914,129	June 22, 1999	Mauskop, A.
6	AB2	6,228,875 B1	May 8, 2001	Tsai, G., <i>et al.</i>
3	AC2	5,684,018	Nov. 4, 1997	Alexander, J.
5	AD2	4,598,094	July 1, 1986	Wurtman, R.J., <i>et al.</i>
5	AE2	5,019,594	May 28, 1991	Wurtman, R.J., <i>et al.</i>
5	AF2	5,422,355	June 6, 1995	White, <i>et al.</i>
5	AG2	4,034,113	July 5, 199	Shulgin
5	AH2	4,479,932	Oct. 30, 1984	Bodor, N.S.
5	AI2	4,636,494	June 13, 1987	Growdon, J.H., <i>et al.</i>
5	AJ2	5,096,712	Mar.17, 1992	Wurtman, R.J.
5	AK2	6,204,245 B1	Mar. 20, 2001	Siegel, J.M., <i>et al.</i>
5	AA3	6,284,760 B1	Sept. 4, 2001	Marston, H.M., <i>et al.</i>
5	AB3	4,105,695	Aug. 8, 1978	Partyka, R.A., <i>et al.</i>
5	AC3	6,251,938 B1	June 26, 2001	Chorev, M., <i>et al.</i>
	AD3			
	AE3			
	AF3			
	AG3			

EXAMINER <i>Bmk</i>	DATE CONSIDERED 3-19-04
---------------------	----------------------------


PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>August 28, 2003</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. <b>3474.1001-001</b> (formerly NIIN-PO1-011)	APPLICATION NO. <b>10/003,740</b>	
	APPLICANT <b>Mel Epstein, <i>et al.</i></b>		
	FILING DATE <b>October 31, 2001</b>	CONFIRMATION NO. <b>2709</b>	GROUP <b>1614</b>

[illegible]

EXAMINER <i>B. K.</i>	DATE CONSIDERED <i>3-18-04</i>
-----------------------	--------------------------------


PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3474.1001-001 (formerly NIIN-PO1-011)	APPLICATION NO. 10/003,740	
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>August 28, 2003</b>  (Use several sheets if necessary)	APPLICANT Mel Epstein, <i>et al.</i>		
	FILING DATE October 31, 2001	CONFIRMATION NO. 2709	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
3	AY2	Yasar, S., <i>et al.</i> , "Preclinical Evaluation of <i>l</i> -Deprenyl: Lack of Amphetamine-Like Abuse Potential," <i>Inhibitors of Monoamine Oxidase B Pharmacology and Clinical Uses in Neurodegenerative Disorders</i> , I. Szelenyi, ed. (Switzerland: Birkhauser Verlag Basel), pp. 215-233 (1993).
3	AZ2	Yasar, S. and Bergman, J., "Amphetamine-like effect of <i>l</i> -deprenyl (selegiline) in drug discrimination studies," <i>Clinical Pharmacology &amp; Therapeutics</i> , 56(6): 768-773 (1994).
3	AR3	Shappell, S.A., <i>et al.</i> , "Stimulated Sustained Flight Operations and Performance, Part 2: Effects of Dextro-Methamphetamine," <i>Military Psychology</i> , 4(4), 267-287 (2002).
3	AS3	Cook, C.E., <i>et al.</i> , "Pharmacokinetics of Methamphetamine Self-Administered to Human Subjects by Smoking S-(+)-Methamphetamine Hydrochloride," <i>Drug Metabolism and Disposition</i> , 21(4): 717-723 (1993).
3	AT3	Vorhees, C.V., <i>et al.</i> , "Adult Learning Deficits After Neonatal Exposure to D-Methamphetamine: Selective Effects on Spatial Navigation and Memory," <i>Journal of Neuroscience</i> , 20(12): 4732-4739 (2000).
3	AU3	Mann, J.J., <i>et al.</i> , "A Controlled Study of the Antidepressant Efficacy and Side Effects of (-)-Deprenyl," <i>Arch Gen Psychiatry</i> , 46: 45-50 (1989).
3	AV3	Kohl, R.L., <i>et al.</i> , "Arousal and Stability: The Effects of five New Sympathomimetic Drugs Suggest a New Principle for the Prevention of Space Motion Sickness," <i>Aviation, Space, and Environmental Medicine</i> : 137-143 (1986).
3	AW3	Wang, J.Q. and McGinty, J.F., "Dose-Dependent Alteration in <i>zif/268</i> and Preprodynorphin mRNA Expression Induced by Amphetamine or Methamphetamine in Rat Forebrain," <i>Journal of Pharmacology and Experimental Therapeutics</i> , 273(2): 909-917 (1995).
3	AX3	Melega, W.P., <i>et al.</i> , "Pharmacokinetic and Pharmacodynamic Analysis of the Actions of D-Amphetamine and D-Methamphetamine on the Dopamine Terminal," <i>Journal of Pharmacology and Experimental Therapeutics</i> , 274(1): 90-96 (1995).
3	AY3	Bisagno, V., <i>et al.</i> , "Short toxic methamphetamine schedule impairs object recognition task in male rats," <i>Brain Research</i> 940: 95-101 (2002).
3	AZ3	Yamamoto, R., and Takasaki, K., "Involvement of Presynaptic $\alpha_2$ -Adrenoreceptors in the Depressor Response Produced by Repeated Administration of Dextro-Methamphetamine," <i>Journal Auton. Pharmac.</i> , 3: 79-88 (1983).

EXAMINER 	DATE CONSIDERED 3/18/04
---	----------------------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>August 28, 2003</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-001 (formerly NIIN-PO1-011)		APPLICATION NO. 10/003,740	
	APPLICANT Mel Epstein, <i>et al.</i>			
	FILING DATE October 31, 2001	CONFIRMATION NO. 2709	GROUP 1614	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
3	AR4 Cappon, G.D. and Vorhees, C.V., "Plasma and brain methamphetamine concentrations in neonatal rats," <i>Neurotoxicology and Teratology</i> , 23: 81-88 (2001).
6	AS4 Gyarmati, Z.S., <i>et al.</i> , "Behavioural Consequences of Methamphetamine-Induced Neurotoxicity in Rats," <i>Neurobiology</i> , 9(1): 37-39 (2001).
3	AT4 Riviere, G.J., <i>et al.</i> , "Spontaneous Locomotor Activity and Pharmacokinetics of Intravenous Methamphetamine and Its Metabolite Amphetamine in the Rat," <i>Journal of Pharmacology and Experimental Therapeutics</i> , 291(3): 1220-1226 (1999).
8	AU4 Haughey, H.M., <i>et al.</i> , "Differential effects of methamphetamine on NA <sup>+</sup> /Cl <sup>-</sup> -dependent transporters," <i>Brain Research</i> , 863: 59-65 (2000).
3	AV4 Caldwell, J., <i>et al.</i> , "Metabolism of [ <sup>14</sup> C]Methamphetamine in Man, the Guinea Pig and the Rat," <i>Biochem. Journal</i> , 129: 11-22 (1972).
6	AW4 Chapman, D.E., <i>et al.</i> , "Long-Term Changes in Basal Ganglia Function after a Neurotoxic Regimen of Methamphetamine," <i>Journal of Pharmacology and Experimental Therapeutics</i> , 296(2): 520-527 (2001).
3	AX4 Melega, W.P., <i>et al.</i> , "Effects of Deprenyl Metabolite, L-Methamphetamine on Striatal Dopamine Efflux," <i>Neurotransmission, Neuromodulation</i> , A376, Abstract No. 2177.
3	AY4 Lin, L.Y., <i>et al.</i> , "Cytochrome P4502D Isozymes Catalyze the 4-Hydroxylation of Methamphetamine Enantiomers," <i>Drug Metabolism and Disposition</i> , 23(6): 610-614 (1995).
6	AZ4 Yanagisawa, Y., <i>et al.</i> , "Association Equilibrium of <i>d</i> -Methamphetamine and <i>l</i> -Methamphetamine With Serum Albumin," <i>Chirality</i> 10: 742-746 (1998).
3	AR5 Melega, W.P., <i>et al.</i> , <i>l</i> -Methamphetamine Pharmacokinetics and Pharmacodynamics for Assessment of <i>in vivo</i> Deprenyl-Derived <i>l</i> -Methamphetamine," <i>Journal of Pharmacology and Experimental Therapeutics</i> , 288(2): 752-758 (1999).
6	ASS Yokel, R.A. and Pickens, R., "Self-Administration of Optical Isomers of Amphetamine and Methylamphetamine by Rats," <i>Journal of Pharmacology and Experimental Therapeutics</i> , 187(1): 27-33 (1973).
3	AT5 Ozaki, T., <i>et al.</i> , "The Adverse Effects of <i>l</i> -Methamphetamine on the Development of Explanted Rat Embryos," <i>Asia-Oceania Journal Obstet. Gynaecol.</i> 18(3): 277-281 (1992).













EXAMINER 	DATE CONSIDERED 3-19-04
---	----------------------------


PTO:1449 REPRODUCED	ATTORNEY DOCKET NO. 3474.1001-001 (formerly NIIN-PO1-011)	APPLICATION NO. 10/003,740	
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>August 28, 2003</b>  (Use several sheets if necessary)	APPLICANT Mel Epstein, <i>et al.</i>		
	FILING DATE October 31, 2001	CONFIRMATION NO. 2709	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
AU5	Vidrio, H., "Cardiovascular Effects of Methamphetamine in Dogs Treated Chronically with the Amine," <i>Journal of Cardiovascular Pharmacology</i> , 4(2): 326-329 (1982).
AV5	Roth, L.W., <i>et al.</i> , "A Comparison of the Analeptic, Circulatory and Other Properties of D- and L-Desoxyephedrine," <i>Arch. int. pharmacyn.</i> , XCVII(3): 362-368 (1954).
AW5	Lehmann, H.E. and Ban, T.A., "Effects of Psychoactive Drugs on Conflict Avoidance Behavior in Human Subjects," <i>Activitas nervosa superior</i> , 13(2): 82-85 (1971).
AX5	Matthews, C., "Overweight Relapse: Effects of Training and Methamphetamine with Pentobarbital," <i>Current Therapeutic Research</i> , 12(1): 34-39 (1970).
AY5	Martin, W.R., <i>et al.</i> , "Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man," <i>Clinical Pharmacology and Therapeutics</i> , 12(2): 245-258 (1970).
AZ5	Shimosato, K., "Urinary Excretion of <i>p</i> -Hydroxylated Methamphetamine Metabolites in Man. II. Effect of Alcohol Intake on Methamphetamine Metabolism," <i>Pharmacology Biochemistry &amp; Behavior</i> , 29: 733-740 (1988).
AR6	Cookson, J. and Silverstone, T., "The Effects of Methamphetamine on Mood and Appetite in Depressed Patients: A Placebo-controlled Study," <i>International Clinical Psychopharmacology</i> , 1: 127-133 (1986).
AS6	Sim, T., <i>et al.</i> , "Cognitive Deficits Among Methamphetamine Users with Attention Deficit Hyperactivity Disorder Symptomatology," <i>Journal of Addictive Diseases</i> , 2(1): 75-89 (2002).
AT6	Comer, S.D., <i>et al.</i> , "Effects of repeated oral methamphetamine administration in humans," <i>Psychopharmacology</i> , 155: 397-404 (2001).
AU6	Mohs, R.C., <i>et al.</i> , "Sensitivity of Some Human Cognitive Functions to Effects of Methamphetamine and Secobarbital," <i>Drug and Alcohol Dependence</i> , 5: 145-150 (1980).
AV6	Mohs, R.C., <i>et al.</i> , "Methamphetamine and Diphenhydramine Effects on the Rate of Cognitive Processing," <i>Psychopharmacology</i> , 59: 13-19 (1978).
AW6	Kopell, B.S. and Wittner, W.K., "The Effects of Chlorpromazine and Methamphetamine on Visual Signal-From-Noise Detection," <i>Journal of Nervous and Mental Disease</i> , 147(4): 418-424 (1968).

EXAMINER <i>Bril</i>	DATE CONSIDERED 3-18-08
-------------------------	----------------------------

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3474.1001-001 (formerly NIIN-PO1-011)	APPLICATION NO. 10/003,740	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT Mel Epstein, <i>et al.</i>		
	FILING DATE October 31, 2001	CONFIRMATION NO. 2709	GROUP 1614
August 28, 2003 (Use several sheets if necessary)			


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
AX6 	Kraemer, T. and Maurer, H.H., "Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine," <i>Journal of Chromatography B</i> , 713: 163-187 (1998).
AY6 	Kraemer, T. and Maurer, H.H., "Toxicokinetics of Amphetamines: Metabolism and Toxicokinetic Data of Designer Drugs, Amphetamine, Methamphetamine, and Their N-Alkyl Derivatives," <i>Therapeutic Drug Monitoring</i> , 24(2): 277-289 (2002).
AZ6 	Berlyne, D.E., "Arousal, Reward and Learning," <i>Annals New York Academy of Sciences</i> , 159(3): 1059-1070 (1969).
AR7 	Chang, L., <i>et al.</i> , "Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users," <i>Psychiatry Research Neuroimaging</i> , 114: 65-79 (2002).
AS7 	Mayfield, D.G., "The Effect of Intravenous Methamphetamine on Mood," <i>International Journal of Addictions</i> , 8(3): 565-568 (1973).
AT7 	Volkow, N.D., <i>et al.</i> , "Loss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence," <i>Journal of Neuroscience</i> , 21(23): 9414-9418 (2001).
AU7 	Herrell, J.M., <i>et al.</i> , "A Multisite Study of the Effectiveness of Methamphetamine Treatment: An Initiative of the Center for Substance Abuse Treatment," <i>Journal of Psychoactive Drugs</i> , 32(2): 143-147 (2000).
AV7 	Perez-Reyes, M., <i>et al.</i> , "Clinical Effects of Methamphetamine Vapor Inhalation," <i>Life Sciences</i> , 49(13): 953-959 (1991).
AW7 	Karch, S.B., <i>et al.</i> , "Methamphetamine-Related Deaths in San Francisco: Demographic, Pathologic, and Toxicologic Profiles," <i>Journal of Forensic Sciences</i> , 44(2): 359-368 (1999).
AX7 	Hart, C.L., <i>et al.</i> , "Methamphetamine self-administration by humans," <i>Psychopharmacology</i> , 157: 75-81 (2001).
AY7 	Lehmann, H.E., <i>et al.</i> , "The Effect of Psychostimulants on Psychometric Test Performance With Special Reference to Conflict Avoidance Behavior," <i>Current Therapeutic Research</i> , 12(6): 390-393 (1970).
AZ7 	Yui, K., <i>et al.</i> , "Noradrenergic activity and spontaneous recurrence of methamphetamine psychosis," <i>Drug and Alcohol Dependence</i> 44: 183-187 (1997).

EXAMINER 	DATE CONSIDERED 3-19-04
---	----------------------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  August 28, 2003  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-001 (formerly NIIN-PO1-011)	APPLICATION NO. 10/003,740	
	APPLICANT Mel Epstein, <i>et al.</i>		
	FILING DATE October 31, 2001	CONFIRMATION NO. 2709	GROUP 1614

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

5	AR8	Perez-Reyes, M., "Differences in Sedative Susceptibility Between Types of Depression," <i>Arch Gen Psychiat</i> , 19: 64-71 (1968).
6	AS8	Shutter, L. and Garell, D.C., "Obesity in Children and Adolescents: A Double-Blind Study with Cross-Over," <i>Journal of School Health</i> , 273-275 (1966).
7	AT8	Ong, Y.L., <i>et al.</i> , "Suppression of Bulimic Symptoms with Methylamphetamine," <i>Brit. Journal Psychiat.</i> , 143: 288-293 (1983).
8	AU8	Kopell, B.S., <i>et al.</i> , "The Effects of Methamphetamine and Secobarbital on the Contingent Negative Variation Amplitude," <i>Psychopharmacologia (Berl.)</i> , 34: 55-62 (1974).
9	AV8	Tariot, P.N., <i>et al.</i> , "Cognitive effects of L-deprenyl in Alzheimer's Disease," <i>Psychopharmacology</i> , 91:489-495 (1987).
10	AW8	Filip, V. and Kolibas, E., "Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial," <i>Journal of Psychiatry &amp; Neuroscience</i> , 24(3): 234-243 (1999).
11	AX8	Finali, G. <i>et al.</i> , "Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy," <i>Ital. J. Neurol. Sci.</i> , 13: 141-148 (1992).
12	AY8	Finali, G., <i>et al.</i> , "L-Deprenyl Therapy Improves Verbal Memory in amnesic Alzheimer Patients," <i>Clinical Neuropharmacology</i> , 14(6): 523-536 (1991).
13	AZ8	Birks, J. and Flicker, L., "Selegiline for Alzheimer's disease," (Cochrane Review). In: <i>The Cochrane Library</i> , Issue 2 (2002). Oxford: Update Software.
14	AR9	Yui, K. and Miura, T., "Behavioral Responses Induced by Repeated Treatment with Methamphetamine Alone and in Combination with Scopolamine in Rats," <i>Neuropsychobiology</i> , 33: 21-27 (1996).
15	AS9	Mewaldt, S.P., and Ghoneim, M.M., "The Effects and Interactions of Scopolamine, Physostigmine and Methamphetamine on Human Memory," <i>Pharmacology Biochemistry &amp; Behavior</i> , 10: 205-210 (1979).
16	AT9	Gordon, M.N., <i>et al.</i> , "Oral Versus Transdermal Selegiline: Antidepressant-Like Activity in Rats," <i>Pharmacology Biochemistry and Behavior</i> , 63(3): 501-506 (1999).
17	AU9	Fang, J. and Yu, P.H., "Effect of L-Deprenyl, its Structural Analogues and some Monoamine Oxidase Inhibitors on Dopamine Uptake," <i>Neuropharmacology</i> , 33(6): 763-768 (1994).

EXAMINER 	DATE CONSIDERED 3-19-02
---	----------------------------




PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>August 28, 2003</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-001 (formerly NIIN-PO1-011)	APPLICATION NO. 10/003,740	
	APPLICANT Mel Epstein, <i>et al.</i>		
	FILING DATE October 31, 2001	CONFIRMATION NO. 2709	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
5	AV9	Czub, M., <i>et al.</i> , "Effects of Selegiline in a retroviral rat model for neurodegenerative disease," <i>Journal of NeuroVirology</i> , 5: 458-464 (1999).
8	AW9	Grasing, K., <i>et al.</i> , "Biphasic Effects of Selegiline on Striatal Dopamine: Lack of Effect on Methamphetamine-Induced Dopamine Depletion," <i>Neurochemical Research</i> , 26(1): 65-74 (2001).
5	AX9	Simpson, L.L., "Evidence That Deprenyl, A Type B Monoamine Oxidase Inhibitor, Is an Indirectly Acting Sympathomimetic Amine," <i>Biochemical Pharmacology</i> , 27: 1591-1595 (1978).
3	AY9	ThyagaRajan, S., <i>et al.</i> , "Region-specific alterations in the concentrations of catecholamines and indoleamines in the brains of young and old F344 rats after L-deprenyl treatment," <i>Brain Research Bulletin</i> , 48(5): 513-520 (1999).
5	AZ9	Mills, D. and Ledger, R., "The Effects of Oral Selegiline Hydrochloride on Learning and Training in the Dog: A Psychobiological Interpretation," <i>Prog. Neuro-Psychopharmacol. &amp; Biol. Psychiat.</i> , 25: 1597-1613 (2001).
5	AR10	Kim, E.M., <i>et al.</i> , "Determination of Enantiomeric Metabolites of L-deprenyl, d-methamphetamine, and racemic methamphetamine in urine by capillary electrophoresis: comparison of deprenyl use and methamphetamine use," <i>Journal. Anal Toxicol.</i> , 24(4): 238-244 (2000 May-June).
8	AS10	Maruyama, W. and Naoi, M., "Neuroprotection by (-)-deprenyl and related compounds," <i>Mechanisms of Ageing and Development</i> , 111: 189-200 (1999).
5	AT10	Matsubara, K., <i>et al.</i> , "L-Deprenyl Prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP+ and $\beta$ -carbolinium: a microdialysis study in rats," <i>Neuroscience Letters</i> , 302: 65-68 (2001).
5	AU10	Dringenberg, H.C., <i>et al.</i> , "Increased effectiveness of tacrine by deprenyl co-treatment in rats: EEG and behavioral evidence," <i>Neuropharmacology and Neurotoxicology</i> , 11(16): 3513-3516 (2000).
3	AV10	Szende, B., <i>et al.</i> , "Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites," <i>Journal Neural. Transm.</i> , 108: 25-33 (2001).
5	AW10	Szoko, E., <i>et al.</i> , "Biotransformation of deprenyl enantiomers," <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 24(4): 315-319 (1999).
5	AX10	Milgram, N.W., <i>et al.</i> , "The Effect of L-Deprenyl on Behavior, Cognitive Function, and Biogenic amines in the Dog," <i>Neurochemical Research</i> , 18(12): 1211-1219 (1993).

EXAMINER	DATE CONSIDERED
----------	-----------------


PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  August 28, 2003  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-001 (formerly NIIN-PO1-011)	APPLICATION NO. 10/003,740	
	APPLICANT Mel Epstein, <i>et al.</i>		
	FILING DATE October 31, 2001	CONFIRMATION NO. 2709	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AY10	3	Sprague, J.E. and Nichols, D.E., "The Monoamine Oxidase-B Inhibitor L-Deprenyl Protects Against 3,4-Methylenedioxymethamphetamine-Induced Lipid Peroxidation and Long-term Serotonergic Deficits," <i>Journal of Pharmacology and Experimental Therapeutics</i> , 273(2): 667-673 (1995).
AZ10	4	Kuhn, D.M., and Geddes, T.J., "Molecular Footprints and Neurotoxic Amphetamine Action," <i>Annals of the New York Academy of Sciences</i> , 914: 92-103 (2000).
AR11	5	Anisman, H. and Waller, T.G., "Effects of Methamphetamine and Shock Duration During Inescapable Shock Exposure on Subsequent Active and Passive Avoidance," <i>Journal of Comparative and Physiological Psychology</i> , 77(1): 143-151 (1971).
AS11	6	Miyamoto, K., "Conditioned Drug Effects of Pimozide, Haloperidol and Chlorpromazine on Methamphetamine-Induced Behavior," <i>Japanese Journal of Psychiatry and Neurology</i> , 44(3): 629-636 (1990).
AT11	7	Yamamura, T., <i>et al.</i> , "Effects of daily administration of methamphetamine on multiple active/passive avoidance performance in rats," <i>Behavioural Brain Research</i> , 53: 105-112 (1993).
AU11	8	Munzar, P., <i>et al.</i> , "Potentiation of the discriminative-stimulus effects of methamphetamine by the histamine H <sub>3</sub> receptor antagonist thioperamide in rats," <i>European Journal of Pharmacology</i> , 363: 93-101 (1998).
AV11	9	Shimada, A., <i>et al.</i> , "Neurochemical Analysis of the Psychotoxicity of Methamphetamine and Cocaine by Microdialysis in the Rat Brain," <i>Annals of the New York Academy of Sciences</i> , 801(1): 361-370 (1996).
AW11	5	Arakawa, O., "Effects of Methamphetamine and Methylphenidate on Single and Paired Rat Open-Field Behaviors," <i>Physiology of Behavior</i> , 55(3): 441-446 (1994).
AX11	9	Plasznik, A. and Kostowski, W., "Effects of p-Bromo-Methamphetamine (V-111) on Conditioned Avoidance Behavior in Rats with Lesioned <i>Raphe Nuclei</i> ," <i>Folia Pharmacol. Pharm.</i> 21, 193-198 (1997).
AY11	8	Metcalfe, F.U., <i>et al.</i> , "Methamphetamine Effects Upon Avoidance Behavior during Limbic Seizures in the Cat," <i>Psychopharmacologia (Berl.)</i> , 21: 390-400 (1971).
AX11	5	Sansone, M., <i>et al.</i> , "Interaction between Nootropic Drugs and Methamphetamine on Avoidance Acquisition but not on Locomotor Activity in Mice," <i>Arch. Int. Pharmacodyn.</i> , 278: 229-235 (1985).

EXAMINER 	DATE CONSIDERED 3-19-04
---	----------------------------


PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3474.1001-001 (formerly NHIN-PO1-011)	APPLICATION NO. 10/003,740	
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>August 28, 2003</b>  (Use several sheets if necessary)	APPLICANT Mel Epstein, <i>et al.</i>		
	FILING DATE October 31, 2001	CONFIRMATION NO. 2709	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
4	AR12 Cho, D., <i>et al.</i> , "Behavioral Teratogenicity of Methamphetamine," Department of Toxicology, National Institute of Safety Research, Seoul, Korea., <i>Journal Toxicol. Sci.</i> , 16 (Supp. 1): 37-49 (1991).
5	AS12 Kasirsky, G. and Tansy, M.F., "Teratogenic Effects of Methamphetamine in Mice and Rabbits," <i>Teratology</i> , 4: 131-134 (1971).
3	AT12 Courtney, K.D. and Valerio, D.A., "Teratology in the <i>Macaca mulatta</i> ," <i>Teratology</i> , 1: 163-172 (1968).
3	AU12 Yamamura, T., <i>et al.</i> , "Effects of Methamphetamine and Ethanol on Learning and Brain Neurotransmitters in Rats," <i>Pharmacology Biochemistry and Behavior</i> , 42: 389-400 (1992).
2	AV12 Moretti, R., <i>et al.</i> , "Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation," <i>International Journal of Geriatric Psychiatry</i> , 17: 391-392 (2002).
2	AW12 Kulig, B. and Calhoun, W.H., "Enhancement of Successive Discrimination Reversal Learning by Methamphetamine," <i>Psychopharmacologia (Berl.)</i> , 27: 233-240 (1972).
2	AX12 Witkin, J.M. <i>et al.</i> , "Behavioral, Toxic and Neurochemical Effects of Sydnocarb, a Novel Psychomotor Stimulant: Comparisons with Methamphetamine," <i>Pharmacology and Experimental Therapeutics</i> , 288(3): 1298-1310 (1999).
3	AY12 Itoh, J., <i>et al.</i> , "Utility of an elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice," <i>European Journal of Pharmacology</i> , 194: 71-76 (1991).
3	AZ12 Glennon, R.A., <i>et al.</i> , "A Preliminary Behavioral Investigation of PMMA, the 4-Methoxy Analog of Methamphetamine," <i>Pharmacology Biochemistry &amp; Behavior</i> , 31: 9-13 (1988).
5	AR13 Wolthuis, O.L., "Experiments With UCB 6215, A Drug Which Enhances Acquisition In Rats: Its Effects Compared With Those of Metamphetamine," <i>European Journal of Pharmacology</i> , 16: 283-297 (1971).
5	AS13 Johnson, B.A., <i>et al.</i> , "Effects of Isradipine, A Dihydropyridine-Class Calcium Channel Antagonist, on D-Methamphetamine-Induced Cognitive and Physiological Changes in Humans," <i>Neuropharmacology</i> , 22(5): 504-512 (2000).
2	AT13 Cook, C.E., <i>et al.</i> , Pharmacokinetics of Oral Methamphetamine and Effects of Repeated Daily Dosing in Humans," <i>Drug Metabolism and Disposition</i> , 20(6): 856-862 (1992).

EXAMINER 	DATE CONSIDERED 3-18-04
--	-------------------------


PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  August 28, 2003  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-001 (formerly NIIN-PO1-011)	APPLICATION NO. 10/003,740	
	APPLICANT Mel Epstein, <i>et al.</i>		
	FILING DATE October 31, 2001	CONFIRMATION NO. 2709	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
5	AU13 Wiegmann, D.A., <i>et al.</i> , "Methamphetamine Effects on Cognitive Processing During Extended Wakefulness," <i>The International Journal of Aviation Psychology</i> , 6(4): 379-397 (1996).
1	AV13 Scheinin, H., <i>et al.</i> , "CYP2D6 polymorphism is not crucial for the disposition of selegiline," <i>Clinical Pharmacology &amp; Therapeutics</i> , 64(4): 402-411 (1998).
3	AW13 Musshoff, F., "Illegal or Legitimate Use? Precursor Compounds to Amphetamine and Methamphetamine," <i>Drug Metabolism Reviews</i> , 32(1): 15-44 (2000).
6	AX13 Cody, J.T., "Metabolic Precursors to Amphetamine and Methamphetamine," <i>Forensic Science Review</i> , 5(2): 110-127 (1993).
2	AY13 Elsworth, J.D., <i>et al.</i> , "The Contribution of Amphetamine Metabolites of (-)-Deprenyl to Its Antiparkinsonian Properties," <i>Journal Neural Transmission</i> , 54: 105-110 (1982).
6	AZ13 Ernst, M., <i>et al.</i> , "Selegiline in Adults With Attention Deficit Hyperactivity Disorder: Clinical Efficacy and Safety," <i>Psychopharmacology Bulletin</i> , 32(3): 327-334 (1996).
3	AR14 Ernst, M., <i>et al.</i> , "Selegiline in ADHD Adults: Plasma Monoamines and Monoamine Metabolites," <i>Neuropsychopharmacology</i> , 16(4): 276-284 (1997).
5	AS14 Heinonen, E., <i>et al.</i> , "Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites," <i>Clinical Pharmacology &amp; Therapeutics</i> , 56(6), part 2, 742-749 (1994).
6	AT14 Van Alvea, O.E., and Donnelly, W.A., "Systemic Effects of Intranasal Medication," <i>Eye, Ear, Nose &amp; Throat Monthly</i> , 31: 476-480 (1952).
7	AU14 Bromage, P.R., "Comparison of Vasoactive Drugs in Man," <i>British Medical Journal</i> , 72-74 (July 12, 1952).
3	AV14 Jirovsky, D., <i>et al.</i> , "The Pilot Study of Methamphetamine Anantiometer Metabolism in Man by Capillary Electrophoresis," <i>Chemica</i> , 40: 25-34 (2001).
5	AW14 Foster, B.S. and Gilbert, D.D., "Enantiomeric Determination of Amphetamine and Methamphetamine in Urine by Precolumn Derivatization with Marfey's Reagent and HPLC," <i>Journal of Analytical Toxicology</i> , 22: 265-269 (1998).

EXAMINER 	DATE CONSIDERED 3-18-04
---	----------------------------


PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>	ATTORNEY DOCKET NO. 3474.1001-001 (formerly NIIN-PO1-011)	APPLICATION NO. 10/003,740	
August 28, 2003  (Use several sheets if necessary)	APPLICANT Mel Epstein, <i>et al.</i>		
	FILING DATE October 31, 2001	CONFIRMATION NO. 2709	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
8	AX14 Teter, D.F., "Metabolism of Diet Pill to Amphetamine and Methamphetamine," (Letters to the Editor), <i>JOEM</i> , 41(3): 139 (1999).
5	AY14 Jirovsky, D., <i>et al.</i> , "Methamphetamine— properties and analytical methods of enantiometer determination," <i>Forensic Science International</i> , 96: 61-70 (1998).
4	AZ14 Cooke, B.J.A., "Chirality of Methamphetamine and Amphetamine from Workplace Urine Samples," <i>Journal of Analytical Toxicology</i> , 18: 49-51 (1994).
5	AR15 Hornbeck, C.L. and Czarney, R.J., "Retrospective Analysis of Some L-Methamphetamine/L-Amphetamine Urine Data," <i>Journal of Analytical Toxicology</i> , 17: 23-25 (1993).
8	AS15 Haley, T.J., "Desoxyephedrine— A Review of the Literature," <i>Journal of the American Pharmaceutical Association</i> , 36(6): 161-169 (1947).
3	AT15 Fitzgerald, R.L., <i>et al.</i> , "Resolution of Methamphetamine Stereoisomers in Urine Testing: Urinary Excretion of R(-)-Methamphetamine Following Use of Nasal Inhalers," <i>Journal of Analytical Toxicology</i> , 12: 255-259 (Sept-Oct. 1988).
4	AU15 Cody, J.T. and Schwarzhoff, R., "Interpretation of Methamphetamine and Amphetamine Enantiomer Data," <i>Journal of Analytical Toxicology</i> , 17: 321-326 (October, 1993).
1	AV15 Ferrando, R.L., <i>et al.</i> , "Bizarre Behavior Following the Ingestion of Levo-Desoxyephedrine," <i>Drug Intelligence and Clinical Pharmacy</i> , 22: 214-216 (1988).
5	AW15 Tatton, W.G., "Selegiline Can Mediate Neuronal Rescue Rather Than Neuronal Protection," <i>Movement Disorder Society</i> , 8(Supp. 1): S20-S30 (1993).
5	AX15 Laine, K., <i>et al.</i> , "Multiple-Dose Pharmacokinetics of Selegiline and Desmethylselegiline Suggest Saturable Tissue Binding," <i>Clinical Neuropharmacology</i> , 23(1): 22-27 (2000).
3	AY15 Ebadi, M., <i>et al.</i> , "Neuroprotective Actions of Selegiline," <i>Journal of Neuroscience Research</i> , 67: 285-289 (2002).
3	AZ15 Dixit, S.N., <i>et al.</i> , "Effect of Selegiline on Cognitive Functions in Parkinson's Disease," <i>JAPI</i> , 47(8): 784-786 (1999).














EXAMINER 	DATE CONSIDERED 3-19-04
---	----------------------------


PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  August 28, 2003  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-001 (formerly NIIN-PO1-011)		APPLICATION NO. 10/003,740	
	APPLICANT Mel Epstein, <i>et al.</i>			
	FILING DATE October 31, 2001	CONFIRMATION NO. 2709	GROUP 1614	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
5	AR16	Bodkin, J.A. and Amsterdam, J.D., "Transdermal Selegiline in Major Depression: a Double-Blind, Placebo-Controlled, Parallel-Group Study in Outpatients," <i>Am. J. Psychiatry</i> , 159(11): 1869-1875 (2002).
6	AS16	Riederer, P. and Przuntek, H. (eds.), "MAO-B-Inhibitor Selegiline (R-(-)-Deprenyl), A New Therapeutic Concept in the Treatment of Parkinson's Disease," <i>Journal of Neural Transmission, Supp.</i> 25: (1987).
7	AT16	Bartzokis, G., <i>et al.</i> , "Selegiline Effects on Cocaine-Induced Changes in Medial Temporal Lobe Metabolism and Subjective Ratings of Euphoria," <i>Neuropsychopharmacology</i> , 20(6): 582-590 (1999).
8	AU16	Alafuzoff, I., <i>et al.</i> , "Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease," <i>Eur. J. Clin Pharmacol</i> , 55: 815-819 (2000).
9	AV16	Yoshida, T., <i>et al.</i> , "Metabolism of deprenyl, a selective monoamine oxidase (MAO) $\beta$ inhibitor in rat: relationship of metabolism to MAO- $\beta$ inhibitory potency," <i>Xenobiotica</i> , 16(2): 129-136 (1986).
10	AW16	Lajtha, A., <i>et al.</i> , "Metabolism of (-)-Deprenyl and PF-(-)-Deprenyl in Brain After Central and Peripheral Administration," <i>Neurochemical Research</i> , 21(10): 1155-1160 (1996).
11	AX16	Golbe, L.I., <i>et al.</i> , "Selegiline and Parkinson's Disease: Protective and Symptomatic Considerations," <i>Drugs</i> , 39(5): 646-651 (1990).
12	AY16	Riley, D.E., "Reversible Transvestic Fetishism in a Man With Parkinson's Disease Treated With Selegiline," <i>Clinical Neuropharmacology</i> , 25(4): 234-237 (2002).
13	AZ16	Heinonen, E.H., <i>et al.</i> , "Pharmacokinetics and Metabolism of Selegiline," <i>Acta Neurol Scand.</i> , 126: 93-99 (1989).
14	AR17	Tariot, P.N., <i>et al.</i> , "L-Deprenyl in Alzheimer's Disease," <i>Arch Gen Psychiatry</i> , 44: 427-433 (1987).
15	AS17	Karoum, F., <i>et al.</i> , "Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: A biochemical assessment," <i>Neurology (Ny)</i> , 32: 503-509 (1982).
16	AT17	Donnan, P.T., <i>et al.</i> , "Selegiline and mortality in subjects with Parkinson's disease: A longitudinal community study," (Reply from the authors), <i>Neurology</i> , 57(2): Correspondence (2001).
17	AU17	Przuntek, H., <i>et al.</i> , "SELEDO: a 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa," <i>European Journal of Neurology</i> , 6: 141-150 (1999).

EXAMINER 	DATE CONSIDERED 3-19-04
---	----------------------------


PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>August 28, 2003</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-001 (formerly NIIN-PO1-011)		APPLICATION NO. 10/003,740	
	APPLICANT Mel Epstein, <i>et al.</i>			
	FILING DATE October 31, 2001	CONFIRMATION NO. 2709	GROUP 1614	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AV17	Schachter, M., <i>et al.</i> , "Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa," <i>Journal of Neurology, Neurosurgery, and Psychiatry</i> , 43: 1016-1021 (1980).
	AW17	Sano, M., <i>et al.</i> , "A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease," <i>The New England Journal of Medicine</i> , 336(17): 1216-1222 (1997).
	AX17	Reynolds, G.P., <i>et al.</i> , "Deprenyl is Metabolized to Methamphetamine and Amphetamine in Man," <i>Br. J. Clin. Pharmacol.</i> , 6: 542-544 (1978).
	AY17	Riederer, P., <i>et al.</i> , "On the Mode of Action of L-Deprenyl in the Human Central Nervous System," <i>Journal of Neural Transmission</i> , 43: 217-226 (1978).
	AZ17	Knoll, J., "The Pharmacology of (-)Deprenyl," <i>Journal Neural Transm. (Suppl)</i> , 22: 75-89 (1986).
	AR18	Knoll, J., "The Possible Mechanisms of Action of (-)Deprenyl in Parkinson's Disease," <i>Journal Neural Transmission</i> , 43: 177-198 (1978).
	AS18	Fowler, J.S., <i>et al.</i> , "Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain," <i>Life Sciences</i> , 68: 2759-2768 (2001).
	AT18	Parkinson Study Group, "Impact of Deprenyl and Tocopherol Treatment on Parkinson's Disease in DATATOP Subjects Not Requiring Levodopa," <i>Annals of Neurology</i> , 39(1): 29-36 (1996).
	AU18	Wilcock, G.K., <i>et al.</i> , "The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials," <i>International Journal of Geriatric Psychiatry</i> 17: 175-183 (2002).
	AV18	Chrisp, P., <i>et al.</i> , "Selegiline: A Review of its Pharmacology, Symptomatic Benefits and Protective Potential in Parkinson's Disease," <i>Drugs &amp; Aging</i> , 1(3): 228-248 (1991).
	AW18	Birkmayer, W., "Long Term Treatment With L-Deprenyl," <i>Journal of Neural Transmission</i> , 43: 239-244 (1978).
	AX18	Csanda, E., <i>et al.</i> , "Experiences With L-Deprenyl in Parkinsonism," <i>Journal Neural Transmission</i> , 43: 263-269 (1978).
	AY18	Larsen, J.P., <i>et al.</i> , "Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study," <i>European Journal of Neurology</i> , 6: 539-547 (1999).

EXAMINER 	DATE CONSIDERED 3-18-00
---	----------------------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>August 28, 2003</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3474.1001-001 (formerly NIIN-PO1-011)	APPLICATION NO. 10/003,740	
	APPLICANT Mel Epstein, <i>et al.</i>		
	FILING DATE October 31, 2001	CONFIRMATION NO. 2709	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
9	AZ18	Bauer and Evey, "Differential Effects of L-Amphetamine on Ontogeny of Active Avoidance, Intertitial Responses, and Locomotor Activity", <i>Psychopharmacology</i> 75: 299-304 (1981).
3	AR19	Yasar, S. <i>et al.</i> , "Evaluation of the Stereoisomers of Deprenyl for Amphetamine-Like Discriminative Stimulus Effects in Rats," <i>J. Pharmacology and Experimental Therapeutics</i> 265: 1-6 (1993).
9	AS19	Brandeis, R. <i>et al.</i> , "Improvement of Cognitive Function by MAO-B Inhibitor L-Deprenyl in Aged Rats," <i>Pharmacology Biochemistry and Behavior</i> , 39: 297-304 (1991).
5	AT19	Mangoni, "Effects of a MAO-B Inhibitor in the Treatment of Alzheimer Disease," <i>Eur Neurol</i> 31: 100-107 (1991).
6	AU19	Kirrane <i>et al.</i> , "Effects of Amphetamine on Visuospatial Working Memory Performance in Schizophrenia Spectrum Personality Disorder," <i>Neuropsychopharmacology</i> 22(1): 14-18 (1999).
3	AV19	Barch, D.M., <i>et al.</i> , "The Effects of D-Amphetamine on Language Function in Schizophrenia," <i>Society for Neuroscience Abstracts</i> 23(1-2):p. 1952 (1997).
9	AW19	Stein, L., <i>et al.</i> , "Memory Enhancement by Central Administration of Norepinephrine," Online Database Biosis, Accession No. PREV197559062381, <i>Brain Research</i> 84(1):329-335 (1975).
7	AX19	Nicholaus, B.J.R., "Symbiotic Approach to Drug Design," <i>Decision Making in Drug Research</i> , pp. 173-186 (1983).
6	AY19	Quartermain, D., <i>et al.</i> , "Alleviation of Scopolamine Amnesia by Different Retrieval Enhancing Treatments," <i>Pharmacol. Biochem. Behav.</i> 30(4):1093-1096 (1988).
5	AZ19	Reus, V.I., <i>et al.</i> , "d-Amphetamine: Effects on memory in a Depressed Population," <i>Biol. Psychol.</i> , 14(2):345-356 (1979).
5	AR20	Yonkov, D.I., "Participation of Cholinergic Mechanics in The Memory Effects of CNS Stimulants," <i>Advanced In The Bioscience, Pergamon Press, GB.</i> , 59: 347-350 (1986).

EXAMINER 	DATE CONSIDERED 3-18-99
--	-------------------------